Dimethylamine

Dimethylamine

SCHEMBL6257995

CNC.NNS(=O)(=O)c1ccccc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.52
▸ CA1 P00915 3/20 0.52
▸ MMP1 P03956 1/20 0.52
▸ MMP2 P08253 1/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ MMP8 P22894 1/20 0.52
▸ MMP13 P45452 1/20 0.52
▸ KEAP1 Q14145 3/20 0.50
▸ IL1RN P18510 1/20 0.50
▸ ERAP1 Q9NZ08 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ GAA P10253 1/20 0.47
▸ BCAT1 P54687 1/20 0.47
▸ PKM P14618 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CA12 O43570 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ CA3 P07451 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL6256599 0.98 CA2 (0.50) CA2CA1MMP1MMP2MMP9
SCHEMBL1109 0.93 CA1 (0.58) CA2CA1MMP1MMP2MMP9
SCHEMBL30724544 0.93 CA1 (0.58) CA2CA1MMP1MMP2MMP9
SCHEMBL29171227 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
Hydrochloric Acid SCHEMBL4638988 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
Potassium SCHEMBL30724545 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
Hydrazine SCHEMBL28166174 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
SCHEMBL29171225 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
Water SCHEMBL1434222 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9
SCHEMBL28202553 0.91 CA1 (0.56) CA2CA1MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1320523-B1 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER LAMBERT CO (US) 2005-06-22 — — EP disclosed
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases WARNER-LAMBERT COMPANY LLC 2005-01-06 — — US disclosed
EP-1320523-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Warner-Lambert Company LLC (US) 2003-06-25 — — EP disclosed
WO-2002024672-A2 BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES WARNER-LAMBERT COMPANY LLC (US) 2002-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004167-A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases BCAT1, BCAT2, ABAT CA2 1859/4885CA1 2034/4885MMP1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback